Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions. These regulatory documents offer detailed insight into the company’s financial condition, risk factors, governance, and product development activities.
CapsoVision’s filings include periodic reports that present net revenue from sales of its CapsoCam Plus capsule endoscopy system, costs of revenue, operating expenses for selling and marketing, research and development, and general and administrative functions, as well as information on cash and cash equivalents and stockholders’ equity. Current Reports on Form 8-K disclose material events such as quarterly financial results, executive appointments or departures, and key regulatory submissions, including applications to the FDA for 510(k) clearance and Breakthrough Device Designation.
On Stock Titan, each new filing from EDGAR is surfaced in near real time and paired with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-page documents, users can review concise highlights of items such as results of operations, changes in leadership, or updates on clinical and regulatory programs for products like CapsoCam Plus, CapsoCam Colon, and CapsoCam UGI.
Investors can also use this page to locate disclosures related to equity structure, the company’s initial public offering, and compensation or appointment details for senior executives, as reported in 8-K filings. By combining direct access to original SEC documents with AI-generated explanations, this section helps users understand how CapsoVision’s regulatory and financial reporting reflects the evolution of its AI-enabled capsule endoscopy business.
CapsoVision, Inc. reported higher Q3 results but remained unprofitable. Net revenue for the three months ended September 30, 2025 was $3.538 million versus $2.966 million a year ago, with gross profit of $1.914 million. Operating expenses rose to $9.933 million, driving a quarterly net loss of $7.921 million and a nine‑month net loss of $17.921 million. Cash and cash equivalents were $17.787 million as of September 30, 2025.
The company completed an IPO in July 2025, raising approximately $23.37 million in net proceeds and converting all preferred stock into common shares after a 1‑for‑3.33 reverse split. Management disclosed that current conditions “raise substantial doubt” about the ability to continue as a going concern. CapsoVision also entered a $4.1 million development agreement with Canon for CMOS sensors, paying $1.0 million at effectiveness and carrying an outstanding purchase commitment of $2.5 million. Revenue was driven mainly by U.S. product sales, while service revenue included cloud delivery and physician reading services.
CapsoVision, Inc. furnished a current report announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. CapsoVision’s common stock trades on Nasdaq under the symbol CV.
CapsoVision, Inc. reported that it issued a press release announcing a 510(k) FDA application for Breakthrough Device Designation for its Pancreatic Cancer Screening Capsule. The disclosure was furnished under Item 8.01 and includes the press release as Exhibit 99.1 dated November 10, 2025.
This notice signals a regulatory step only; it does not reflect FDA clearance or authorization. The company did not disclose financial terms or operational changes in this update.
CapsoVision (CV) reported a Form 4 for David Garcia, Sr. VP of Finance. On 11/03/2025, he received a stock option grant for 165,000 shares at an exercise price of $4.78 per share, expiring 11/03/2035. The filing lists ownership of these derivative securities as direct.
The options vest as to 25% on November 3, 2026, with the remaining 75% vesting in 36 equal monthly installments through November 3, 2029, contingent on continued service.
CapsoVision, Inc. (CV) filed a Form 3 for an officer reporting no holdings. On 11/03/2025, Senior Vice President of Finance David Garcia submitted an initial statement of beneficial ownership indicating no securities are beneficially owned.
The filing was executed via Power of Attorney by Kang-Huai (Johnny) Wang. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in ownership.
CapsoVision, Inc. appointed David Garcia as principal financial officer and principal accounting officer, effective November 3, 2025. Garcia brings more than 20 years of finance leadership experience, most recently serving as VP of Financial Planning and Analysis at Matterport from October 2020 to October 2025, with prior senior roles at View, Intelepeer, and Align Technology.
His compensation includes a $300,000 annual base salary, an option to purchase 165,000 shares granted on November 3, 2025 at the closing share price that day, and a $12,500 quarterly bonus. Vesting is structured with 25% on November 3, 2026, and the remainder in 36 equal monthly installments thereafter. The company entered into its standard indemnification agreement with Garcia. The company reported no arrangements leading to his appointment and no related-party relationships under Item 404(a). A press release announcing the appointment was furnished as Exhibit 99.1.
Tsai Chen Lung, a director of CapsoVision, Inc. (CV), reported receipt of 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents a contingent right to one share of the company’s common stock and the reported RSUs carry a $0 price. The RSUs are scheduled to vest on December 31, 2025, and following the reported transaction the filing shows 2,887 shares beneficially owned directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/17/2025.
CapsoVision, Inc. (CV) director Hui Ying Kuo received 2,887 Restricted Stock Units (RSUs) in a non‑derivative issuance dated 09/15/2025. Each RSU represents the contingent right to one share of common stock, and the RSUs are scheduled to vest on 12/31/2025. Following the reported grant the reporting person beneficially owns 2,887 shares on a direct basis at a $0 per‑share issuance price. The Form 4 was filed to disclose this issuance under Section 16 reporting rules; no options, dispositions, or other classes of securities are reported on this form.
CapsoVision, Inc. (CV) director Wen-Herng Henry received a grant of 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents a contingent right to one share of the company's common stock and the RSUs are scheduled to vest on 12/31/2025. The reported grant carries a $0 price per unit and, after the grant, Mr. Henry beneficially owns 2,887 shares attributable to these RSUs on a direct basis. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/17/2025.
FAQ
What is the current stock price of CapsoVision (CV)?
What is the market cap of CapsoVision (CV)?
